Why Denali Therapeutics' Stock Rose 6.6% on Wednesday

Why Denali Therapeutics' Stock Rose 6.6% on Wednesday

Submitted by admin on November 2, 2022 - 10:51pm
Source: 
Motley Fool
News Tags: 
Denali Therapeutics
clinical trials
Alzheimer's disease
TAK-594
Headline: 
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
snippet: 
  • Denali Therapeutics specializes in treating neurodegenerative disorders.
  • The company released preliminary phase 1/2 data on an Alzheimer's therapy.
  • Denali isn't profitable, but it does have $1.16 billion in cash.

Do Not Allow Advertisers to Use My Personal information